share_log

Even After Rising 19% This Past Week, Hunan Jingfeng PharmaceuticalLtd (SZSE:000908) Shareholders Are Still Down 49% Over the Past Five Years

Even After Rising 19% This Past Week, Hunan Jingfeng PharmaceuticalLtd (SZSE:000908) Shareholders Are Still Down 49% Over the Past Five Years

即使在过去一周上涨了19%之后,湖南景峰药业有限公司(深圳证券交易所代码:000908)的股东在过去五年中仍下跌了49%
Simply Wall St ·  03/20 19:57

This month, we saw the Hunan Jingfeng Pharmaceutical Co.,Ltd. (SZSE:000908) up an impressive 84%. But if you look at the last five years the returns have not been good. You would have done a lot better buying an index fund, since the stock has dropped 49% in that half decade.

这个月,我们看到了湖南景峰药业有限公司。, Ltd.(深圳证券交易所股票代码:000908)上涨了令人印象深刻的84%。但是,如果你看看过去的五年,回报并不理想。购买指数基金的表现要好得多,因为该股在那五年中下跌了49%。

The recent uptick of 19% could be a positive sign of things to come, so let's take a look at historical fundamentals.

最近19%的上涨可能是即将发生的事情的积极信号,因此让我们来看一下历史基本面。

Hunan Jingfeng PharmaceuticalLtd wasn't profitable in the last twelve months, it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). Arguably revenue is our next best option. When a company doesn't make profits, we'd generally expect to see good revenue growth. Some companies are willing to postpone profitability to grow revenue faster, but in that case one does expect good top-line growth.

湖南景峰制药有限公司在过去十二个月中没有盈利,我们不太可能看到其股价与每股收益(EPS)之间存在很强的相关性。可以说,收入是我们的下一个最佳选择。当一家公司没有盈利时,我们通常预计收入会有良好的增长。一些公司愿意推迟盈利以更快地增加收入,但在这种情况下,人们确实预计收入会有良好的增长。

Over half a decade Hunan Jingfeng PharmaceuticalLtd reduced its trailing twelve month revenue by 30% for each year. That's definitely a weaker result than most pre-profit companies report. It seems pretty reasonable to us that the share price dipped 8% per year in that time. This loss means the stock shareholders are probably pretty annoyed. It is possible for businesses to bounce back but as Buffett says, 'turnarounds seldom turn'.

在过去的五年中,湖南景峰制药有限公司过去十二个月的收入每年减少30%。这绝对比大多数盈利前公司报告的结果要差。在我们看来,当时股价每年下跌8%,这似乎是合理的。这种损失意味着股票股东可能非常生气。企业有可能反弹,但正如巴菲特所说,“转机很少会转机”。

The graphic below depicts how earnings and revenue have changed over time (unveil the exact values by clicking on the image).

下图描述了收入和收入随时间推移而发生的变化(点击图片即可显示确切的数值)。

earnings-and-revenue-growth
SZSE:000908 Earnings and Revenue Growth March 20th 2024
SZSE: 000908 2024年3月20日收益和收入增长

If you are thinking of buying or selling Hunan Jingfeng PharmaceuticalLtd stock, you should check out this FREE detailed report on its balance sheet.

如果你想买入或卖出湖南景丰制药有限公司的股票,你应该查看这份关于其资产负债表的免费详细报告。

A Different Perspective

不同的视角

Hunan Jingfeng PharmaceuticalLtd shareholders are down 11% over twelve months, which isn't far from the market return of -11%. However, the loss over the last year isn't as bad as the 8% per annum loss investors have suffered over the last half decade. Generally speaking we'd prefer see an improvement in the fundamental metrics before becoming enthusiastic about the stock. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Take risks, for example - Hunan Jingfeng PharmaceuticalLtd has 2 warning signs we think you should be aware of.

湖南景峰制药有限公司股东在十二个月内下跌了11%,与-11%的市场回报率相差不远。但是,去年的亏损并不像投资者在过去五年中遭受的每年8%的亏损那么严重。总的来说,在对股票产生热情之前,我们希望看到基本面指标的改善。我发现将长期股价视为业务绩效的代表非常有趣。但是,要真正获得见解,我们还需要考虑其他信息。例如,冒险吧——湖南景峰制药有限公司有两个警示信号,我们认为你应该注意。

We will like Hunan Jingfeng PharmaceuticalLtd better if we see some big insider buys. While we wait, check out this free list of growing companies with considerable, recent, insider buying.

如果我们看到一些重大的内幕收购,我们会更喜欢湖南景峰制药有限公司。在我们等待的同时,可以免费查看这份最近有大量内幕收购的成长型公司名单。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.

请注意,本文引用的市场回报反映了目前在中国交易所交易的股票的市场加权平均回报。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发